Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
McKinsey
Colorcon
Merck
Boehringer Ingelheim

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

MINIPRESS Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Minipress, and what generic alternatives are available?

Minipress is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in MINIPRESS is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Minipress

A generic version of MINIPRESS was approved as prazosin hydrochloride by TEVA PHARMS on September 12th, 1988.

  Try it Free

Drug patent expirations by year for MINIPRESS
Drug Prices for MINIPRESS

See drug prices for MINIPRESS

Recent Clinical Trials for MINIPRESS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yale UniversityPhase 1/Phase 2
University of WashingtonPhase 4
Johns Hopkins UniversityPhase 2

See all MINIPRESS clinical trials

Pharmacology for MINIPRESS
Paragraph IV (Patent) Challenges for MINIPRESS
Tradename Dosage Ingredient NDA Submissiondate
MINIPRESS CAPSULE;ORAL prazosin hydrochloride 017442

US Patents and Regulatory Information for MINIPRESS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-002 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-002 Jan 29, 1992 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MINIPRESS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-001 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-002 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-001 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
AstraZeneca
McKesson
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.